Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06657248

Clinical Performance and Safety of the Unicompartmental Univation® XF Pro Implant

The study is designed as a prospective, observational, mid-term, multi-center follow-up study. It is planned to include 150 patients from 4 different study centres in Germany.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Oberlinklinik gGmbH, Potsdam, Brandenburg, Germany

Loading trial locations.

About this study

The product under investigation is used in routine clinical practice and according to the authorized Instructions for Use (IfU). The data that is obtained in routine clinical use will be documented in an electronical Case Report Form (eCRF). The study's main purpose is the collection of clinical data on the safety and performance of the redesigned univation® XF Pro implant.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Indication for a primary medial unicompartmental knee endoprosthesis

Acc. to Instructions for Use:

  • Both cruciate ligaments intact
  • Lateral ligaments intact
  • Leg axis amenable to passive correction
  • Varus deformity under 15°
  • Bending capability of at least 90°
  • Extension deficit no greater than 5-10°
  • Written informed consent of patient
  • Kellgran & Lawrence Score > II (only straight or varus
  • Patients with moderate radiological symptoms
  • Patients without clinical symptoms

Exclusion criteria

  • Pregnancy
  • Patient age <18 and > 75 years
  • BMI ≥ 40
  • High risk patients ASA > III

Treatment and study plan

univation® XF Pro

Device

Primary medial unicompartmental knee arthroplasty

Other names: Unicompartmental knee arthroplasty

Primary outcomes

  1. Functional patient-reported outcome

    Time frame: 5 years post-op

    The Oxford Knee Score (OKS) is a reliable 12-item, patient-reported questionnaire originally developed and validated specifically to assess function and pain in patients undergoing total knee replacement. It is short, reproducible, valid and sensitive to clinically important changes over time. Each of the 12 questions on the OKS is scored in the same way with the score decreasing as the reported symptoms increase (i.e. become worse). All questions are laid out with response categories denoting least (or no) symptoms to the left of the page (scoring 4) and those representing greatest severity lying on the right hand side (scoring 0), as detailed for question 1 below. This method, when summed, produces overall scores running from 0 to 48 with 48 being the best outcome.

Secondary outcomes

  1. Implant survival [Kaplan-Meier]

    Time frame: until 5 years postoperatively

    Kaplan-Meier Analysis is a standard statistical method to describe the survival of human subjects or medical products over a defined time period.

  2. Quality of Life [EQ-5D-5L] compared to baseline

    Time frame: Preoperatively (baseline) and 3 months, 1 year, 2 years, 5 years postoperatively

    The 5-dimension 5-level measure of the health status, developed by the EuroQol Group (EQ-5D-5L) is a simple and generic measure for clinical and economic assessment. Instructions for the user are directly included into the questionnaire and it consists of two pages. One cover five different dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression) and the other one the EQ visual Analogue Scale (EQ-VAS). The VAS scale records the self rated health status of the patient from the level "the worst health you can imagine" to "the best health you can imagine".

    The answer of each of the five dimensions result in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

  3. Progress of Clinical Outcome [Forgotten Joint Score-12] over follow-up period

    Time frame: 3 months, 1 year, 2 years, 5 years postoperatively

    The Forgotten Joint Score-12 (FJS-12) Knee was designed to assess patient outcome in patients undergoing conservative or operative treatment of the knee. These Patient Reported Outcome (PRO) questionnaires focus on patients' awareness of a specific joint in everyday life. In 12 Items the awareness for the artificial joint is assessed by the patient, each on a five point scale (Never / Almost Never / Seldom / Sometimes / Mostly) The Forgotten Joint Score assessment consists of 12 questions and is scored on a 0-100 scale. The higher the score, the less the patient is aware of their affected joint when performing daily activities

  4. Radiological assessment: axis alignment (long leg x-ray) over time

    Time frame: at discharge (approx. 7-10 days postoperatively), 3 months, 1 year, 2 years, 5 years postoperatively

    Radiographs shall be standardized between centres as far as possible. Unless limited by patient or equipment constraints, all follow-up imaging examinations will be obtained according to the radiographic protocol of the hospital and the set routine. The radiographic evaluation of Alignment is based on long-leg x-rays

  5. Radiological assessment: comparison of tibial slope over time

    Time frame: at discharge (approx. 7-10 days postoperatively), 3 months, 1 year, 2 years, 5 years postoperatively

    Radiographs shall be standardized between centres as far as possible. Unless limited by patient or equipment constraints, all follow-up imaging examinations will be obtained according to the radiographic protocol of the hospital and the set routine. Any changes of Tibial slope over the follow-up period is documented in the radiographic evaluation

  6. Radiological assessment: Patella x-ray

    Time frame: at discharge (approx. 7-10 days postoperatively), 3 months, 1 year, 2 years, 5 years postoperatively

  7. Number of Adverse events / serious adverse events over time

    Time frame: During the course of the study up to 5 years postoperatively

    During the course of the study, any upcoming intra- or postoperative (serious) adverse events (AE / SAE) or device effects related or not related to the product under investigation or the procedure, will be documented in the dedicated Case Report Forms. The total number of AEs will be summarized and further evaluated by the sponsor and reported according to local legislation and necessity. Recorded complications will be categorized and analyzed in order to assess the safety of the investigational product

  8. Number of Participants with radiological complications over time

    Time frame: During the course of the study up to 5 years postoperatively

    Radiographs shall be standardized between centres as far as possible. Unless limited by patient or equipment constraints, all follow-up imaging examinations will be obtained according to the radiographic protocol of the hospital and the set routine. All radiologically evident complications (including fracture, wear, loosening or radiolucencies) are cumulatively documented over the period of follow-up.

Study contacts

Contact information is provided by the study sponsor or research team.

Petra Wain

CONTACT

[email protected]

+49746195

Stefan Maenz, Dr.

CONTACT

[email protected]

+49746195

Sponsors and collaborators

Lead sponsor

Aesculap AG

Industry

Collaborators

  • Raylytic GmbH

Registry information

Official study title

Prospective, Multicenter Study Evaluating the Midterm Clinical Performance and Safety of the Unicompartmental Univation® XF Pro Knee Implant

Acronym: UNI_XF_PRO

Important dates

Study start
2026
Primary completion
2027
Study completion
2032
First posted
Oct 24, 2024
Registry last updated
May 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.